This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Wegovy is administered once weekly on the same day each week through subcutaneous injection into the thigh, abdomen, or upper arm, with sites rotated to prevent skin irritation. Proper injection ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days ...

Tirzepatide vs. semaglutide, which is better? Medical experts agree that tirzepatide has better results, but the right drug ...

People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further ...

Natco Pharma has launched the Semaglutide injection in India on the first day of its patent expiry. Hyderabad-based Natco received approval from Central Drugs Standard Control Organisation (CDSCO) to ...

NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse ...

More than a million patients who have had a heart attack or stroke and are overweight will now be eligible for weight loss ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Nausea is the most common side effect of semaglutide, the weight loss and diabetes medication sold under the brand names Ozempic and ...